Xdx

Achaogen, based in South San Francisco, CA, is a pharmaceutical company that specializes in the development and production of innovative treatments for complicated urinary tract infections (cUTI). Their flagship product, ZEMDRI plazomicin injection, is approved for use in the United States and is indicated for the treatment of cUTI caused by certain susceptible microorganisms. Achaogen is committed to providing healthcare professionals with effective and safe treatment options for patients with limited or no alternative therapies. With a focus on addressing the challenges of treating cUTI, Achaogen's ZEMDRI offers a mechanism of action that helps combat the infection caused by specific Enterobacterales. The company emphasizes the importance of using ZEMDRI only for proven or strongly suspected infections caused by susceptible microorganisms, and highlights the need for regular monitoring of renal function due to the risk of nephrotoxicity. Achaogen's dedication to research and development, along with their partnership with Tanner Pharma Group for international access, demonstrates their commitment to improving patient outcomes in the field of urinary tract infections.Generated from the website